Nexthera Capital's 13F Holdings Comparison: Q1 2019 vs Q2 2019

In the world of finance, investment managers need to file a quarterly report known as Form 13F with the Securities and Exchange Commission. This report includes information on the investment manager's holdings in various stocks, bonds, and other securities. The report is used by investors and analysts to assess the investment strategy of a particular fund or investment manager.

One such investment manager is Nexthera Capital LP, which recently filed its 13F report for the first and second quarters of 2019. Looking at the data, it's clear that Nexthera Capital has made several changes to its holdings during this time period.

One of the most significant changes is in its holdings of Intercept Pharmaceuticals Inc (ICPT). In the first quarter of 2019, Nexthera Capital held 11,952 shares of the company, worth $1.3 million. By the end of the second quarter, it had increased its holdings to 152,441 shares, worth over $8 million. That's an increase of over 1,200% in just three months.

Another company that saw a significant increase in Nexthera Capital's holdings is Insmed Inc (INSM). In the first quarter, the investment manager held 284,263 shares in Insmed, worth $8.2 million. By the end of the second quarter, it had increased its holdings to 470,741 shares, worth over $12 million. That's an increase of nearly 66%.

Audentes Therapeutics Inc (BOLD) also saw a slight increase in Nexthera Capital's holdings, from 250,620 shares worth $9.8 million in the first quarter to 294,013 shares worth $11.1 million in the second quarter, a 13.8% increase.

On the other hand, some companies saw a decrease in Nexthera Capital's holdings. Allergan PLC (AGN), for example, saw a decrease in holdings from 13,700 shares worth $2 million in the first quarter to just 3,347 shares worth $560,000 in the second quarter, a decrease of 72.1%.

Other companies that saw a complete exit from Nexthera Capital's portfolio in the second quarter include Heron Therapeutics Inc (HRTX), Bausch Health Cos Inc (BHC), Stemline Therapeutics Inc (STML), and Novartis AG (NVS).

As an investment manager, Nexthera Capital's primary goal is to maximize returns for its investors. To achieve this, it must continuously monitor its holdings and make adjustments when necessary. Looking at the changes in its 13F holdings between Q1 and Q2 2019, it's clear that Nexthera Capital is actively managing its portfolio to ensure it's well-positioned for success in the future.